Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesViridian Therapeutics Inc

Viridian Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
29.975 USD 1.49 ( 5.21%)
Last update at 2026-11-09T20:53:00Z
VOLUME
3067495
Market Cap
2473.17M

Momentum Score

…

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
28.60
Low
30.38
High
52 Week Price Range
13.18
Low
34.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for thyroid eye disease and related ophthalmic and fibrotic disorders. Long-term growth may be driven by clinical trial readouts, regulatory approvals, potential label expansion and strategic collaborations. Investors may find exposure attractive because the company appears positioned to generate meaningful value from positive late-stage data.
Material investment risks include high clinical and regulatory failure risk, competition from established therapies, ongoing negative earnings with potential need for additional financing and execution risk; investors should monitor trial outcomes and cash runway.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
28.49
Dividend Yield
-
Revenue TTM
71.13M
Revenue Per Share
0.74
Gross Profit TTM
-253.55M
Debt / Equity
0.07
ROE
-65.74%
Net Debt
-161.69M
ROCE
-40.74%
Diluted EPS TTM
-3.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -342.60M -269.95M -237.73M -129.87M -79.41M
Net income -342.60M -269.95M -237.73M -125.44M -79.42M
Selling general administrative 95.31M 61.08M 95.00M 35.18M 25.80M
Gross profit 70.85M 0.30M 0.31M 1.77M 2.96M
Reconciled depreciation 0.46M 0.54M 0.47M 0.26M 0.12M
Ebit -337.65M -266.90M -235.89M -134.30M -79.73M
Ebitda -337.19M -265.66M -235.37M -129.39M -79.29M
Depreciation and amortization 0.46M 1.24M 0.52M 4.92M 0.44M
Non operating income net other - - - 4.68M 0.17M
Operating income -363.39M -299.04M -254.45M -134.30M -79.73M
Other operating expenses 434.24M 299.34M 254.76M 136.08M 82.69M
Interest expense 4.95M 3.05M 1.85M 0.49M 0.00M
Interest income 27.40M 32.13M 16.48M 4.92M 0.32M
Net interest income 22.45M 29.09M 15.38M 4.43M 0.32M
Income tax expense - -269.95M 18.56M -4.43M 0.00M
Total revenue 70.85M 0.30M 0.31M 1.77M 2.96M
Total operating expenses 434.24M 299.34M 254.76M 136.08M 82.69M
Cost of revenue 1.16M 1.24M 1.32M - -
Total other income expense net 20.79M 29.09M 16.72M 4.43M 0.32M
Net income from continuing ops -342.60M -269.95M -216.66M -130.11M -79.56M
Net income applicable to common shares - - - -129.87M -79.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 899.42M 742.40M 490.42M 435.09M 203.71M
Other current assets 19.58M 20.88M 9.01M 6.52M 2.75M
Total liab 177.25M 70.76M 48.40M 40.03M 15.99M
Total stockholder equity 722.17M 671.64M 442.02M 395.06M 187.72M
Other current liab 60.89M 44.93M 23.27M 18.21M 10.50M
Common stock 1.02M 0.81M 0.54M 0.41M 0.24M
Capital stock 133.07M 189.69M 207.06M 142.56M 134.07M
Retained earnings -1338.46M -995.86M -725.91M -488.17M -358.30M
Other liab - - - 0.93M 2.36M
Other assets - - - 0.98M 318.13M
Cash 212.38M 99.59M 102.83M 155.58M 42.30M
Total current liabilities 70.70M 47.87M 26.64M 33.35M 13.64M
Current deferred revenue 0.37M 0.29M 0.29M 0.29M 0.29M
Net debt -161.69M -78.50M -81.78M -150.32M -41.78M
Short term debt 0.75M 0.51M 0.84M 0.61M 0.52M
Short long term debt total 50.69M 21.09M 21.05M 5.26M 0.52M
Other stockholder equity 1927.10M 1477.81M 960.54M 741.07M 412.10M
Property plant equipment - - - 1.33M 0.38M
Total current assets 894.23M 738.46M 486.48M 424.55M 200.16M
Net tangible assets - - - 252.92M 53.88M
Short term investments 662.27M 617.99M 374.54M 268.97M 154.67M
Net receivables - - 0.10M 0.10M 0.45M
Long term debt 49.94M 20.58M 20.20M 4.64M -
Inventory - - - -6.62M -
Accounts payable 8.68M 2.14M 2.24M 14.23M 2.33M
Accumulated other comprehensive income 0.45M -0.01M 0.34M -0.39M -0.16M
Common stock total equity - - - 0.41M 0.24M
Preferred stock total equity - - - 142.15M 133.83M
Retained earnings total equity - - - -488.17M -358.30M
Non currrent assets other 1.54M 0.50M 0.60M 7.61M 1.49M
Non current assets total 5.18M 3.94M 3.95M 10.54M 3.55M
Capital lease obligations 0.75M 0.51M 0.84M 0.61M 0.52M
Long term debt total - - - 4.64M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -37.07M -228.65M -105.14M -114.33M -74.03M
Change to liabilities - - - 19.24M 3.04M
Total cashflows from investing activities -37.56M -228.65M -94.25M -115.13M -74.29M
Net borrowings 28.88M 0.00M 15.00M 4.55M 5.00M
Total cash from financing activities 426.74M 457.74M 225.67M 322.24M 125.28M
Change to operating activities - - - 4.38M -0.12M
Net income -342.60M -269.95M -237.73M -129.87M -79.41M
Change in cash 112.79M -3.23M -52.75M 113.28M -3.60M
Begin period cash flow 99.59M 102.83M 155.58M 42.30M 45.90M
End period cash flow 212.38M 99.59M 102.83M 155.58M 42.30M
Total cash from operating activities -276.39M -232.32M -184.17M -93.84M -54.58M
Issuance of capital stock 352.20M 478.66M 25.09M 335.87M 131.20M
Depreciation -6.76M 0.54M 0.52M 0.26M 0.12M
Other cashflows from investing activities - -228.65M - - 0.08M
Dividends paid - - 14.49M - -
Change to account receivables - 0.10M - 0.35M -0.45M
Sale purchase of stock 1.12M - 0.58M 0.18M 125.28M
Other cashflows from financing activities 49.54M 4.08M 85.60M 30.63M 11.03M
Change to netincome - - - 19.77M 22.04M
Capital expenditures 0.49M 0.51M 0.90M 0.80M 0.34M
Cash flows other operating - - - -3.24M -1.42M
Cash and cash equivalents changes - - - 113.28M -3.60M
Change in working capital 23.03M 9.60M -9.43M 15.96M 1.72M
Stock based compensation 44.30M 42.15M 67.17M 19.77M 14.46M
Other non cash items 5.63M -14.66M -4.71M 0.05M 7.49M
Free cash flow -276.89M -232.83M -185.07M -94.64M -54.92M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VRDN
Viridian Therapeutics Inc		 1.49
5.21%		 29.98 - 1.01 34.77 4.46 26.37 -3.18
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Viridian Therapeutics Inc

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

221 Crescent Street, Waltham, MA, United States, 02453

617 272 4600

https://www.viridiantherapeutics.com

252

Name Title Year Born
Dr. Jonathan Violin M.B.A., Ph.D. Co-Founder, CEO, Pres & Director 1975
Mr. Kristian Humer M.B.A. CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer 1975
Dr. Barrett Katz CMO, M.B.A., M.D., MBA Chief Medical Officer 1950
Dr. Eric N. Olson Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder & Member of the Scientific Advisory Board 1945
Dr. Marvin H. Caruthers Ph.D. Co-Founder & Scientific Advisory Board Member 1940
Mr. Vahe Bedian Ph.D. Co-Founder & Scientific Advisor NA
Ms. Carrie Melvin M.B.A. Chief Operating Officer NA
Dr. Rob Henderson Ph.D. Chief Scientific Officer NA
Mr. Todd James IRC Sr. VP of Corp. Affairs & Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…